12.55
-0.8(-5.99%)
Currency In USD
| Previous Close | 13.35 |
| Open | 13.6 |
| Day High | 13.6 |
| Day Low | 12.5 |
| 52-Week High | 19.77 |
| 52-Week Low | 7.58 |
| Volume | 284,210 |
| Average Volume | 219,590 |
| Market Cap | 475.22M |
| PE | -4.11 |
| EPS | -3.05 |
| Moving Average 50 Days | 11.3 |
| Moving Average 200 Days | 12.32 |
| Change | -0.8 |
If you invested $1000 in Celcuity Inc. (CELC) since IPO date, it would be worth $878.24 as of July 01, 2025 at a share price of $12.55. Whereas If you bought $1000 worth of Celcuity Inc. (CELC) shares 5 years ago, it would be worth $1,805.76 as of July 01, 2025 at a share price of $12.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
GlobeNewswire Inc.
Yesterday at 11:05 AM GMT
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66% • In a
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
GlobeNewswire Inc.
May 21, 2025 11:05 AM GMT
MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewswire Inc.
May 07, 2025 11:05 AM GMT
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first qua